Kodiak SciencesKOD
KOD
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
306% more capital invested
Capital invested by funds: $103M [Q3] → $418M (+$315M) [Q4]
101% more call options, than puts
Call options by funds: $543K | Put options by funds: $270K
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
9% more funds holding
Funds holding: 97 [Q3] → 106 (+9) [Q4]
4.98% more ownership
Funds ownership: 74.94% [Q3] → 79.92% (+4.98%) [Q4]
3% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 30
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3
16%
upside
Avg. target
$3
16%
upside
High target
$3
16%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Matthew Caufield 35% 1-year accuracy 22 / 63 met price target | 16%upside $3 | Neutral Reiterated | 31 Mar 2025 |
Financial journalist opinion
Based on 5 articles about KOD published over the past 30 days
Positive
Zacks Investment Research
4 hours ago
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD)
Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Negative
Zacks Investment Research
4 days ago
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.

Neutral
PRNewsWire
4 days ago
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
PALO ALTO, Calif. , March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024.

Positive
Zacks Investment Research
3 weeks ago
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate
Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.

Neutral
PRNewsWire
3 weeks ago
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance PALO ALTO, Calif.

Positive
Seeking Alpha
1 month ago
Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders
Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD's pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027.

Neutral
PRNewsWire
1 month ago
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
PALO ALTO, Calif. , Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA.

Neutral
PRNewsWire
2 months ago
Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
PALO ALTO, Calif. , Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D.

Positive
Zacks Investment Research
2 months ago
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.

Positive
Zacks Investment Research
3 months ago
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.

Charts implemented using Lightweight Charts™